Edwards Lifesciences Shares Rise 22.1% Over the Past Year: What Are the Key Factors?

Edwards Lifesciences: A Year of Strong Growth

Over the past year, shares of Edwards Lifesciences (EW) have surged by 22.1%, significantly outperforming the broader medical products sector, which declined by 3.8%. This performance nearly matched the S&P 500 composite’s 23.5% gain during the same period.

Business Highlights and Recent Developments

Currently holding a Zacks Rank #2 (Buy), Edwards Lifesciences has demonstrated steady expansion in its Transcatheter Mitral and Tricuspid Therapies (TMTT) division, while also scaling up its rapidly growing business lines. The company’s Transcatheter Aortic Valve Replacement (TAVR) platform has benefited from technological advancements, such as the RESILIA tissue, and broader international adoption. Additionally, the Surgical Structural Heart segment continues to see strong demand for its advanced surgical solutions worldwide.

Headquartered in Irvine, California, Edwards Lifesciences specializes in innovative products for treating complex cardiovascular conditions, with a focus on structural heart disease in critically ill patients. On September 3, 2024, the company finalized the sale of its Critical Care division to Becton, Dickinson, and Company for $4.2 billion in cash. This move has enhanced Edwards’ financial flexibility, enabling further investment in technologies for aortic, mitral, tricuspid, and pulmonic valve patients, as well as new interventional heart failure therapies.

Key Drivers Behind the Stock’s Uptrend

The company’s share price momentum is largely attributed to ongoing success in the TMTT segment, fueled by the global uptake of the PASCAL and EVOQUE systems. Drawing on insights from clinical trials and real-world data, Edwards has built a robust portfolio of transcatheter solutions for both mitral and tricuspid valve repair and replacement. The company remains optimistic about its growth trajectory and continues to expand its business at a rapid pace.

With the finalized National Coverage Determination, the EVOQUE system will become available to all Medicare patients with symptomatic tricuspid regurgitation starting March 2025. In April 2025, the SAPIEN M3 mitral valve replacement system received CE Mark approval for treating patients with moderate-to-severe or severe mitral regurgitation who are not candidates for surgery or TEER therapy.

For the fifth straight quarter, TAVR sales surpassed $1 billion in Q4 2025, reflecting clinicians’ increased focus on SAPIEN therapy and proactive management of severe aortic stenosis. Edwards maintained a strong competitive position and stable pricing worldwide. In Europe, the company reported solid growth in TAVR procedures and consistent execution across the region.

Following CE Mark approval for the Alterra system, designed for congenital heart patients, Edwards has begun introducing this therapy in Europe, with initial feedback from clinicians being favorable.

In 2025, the Surgical Structural Heart business experienced robust growth, driven by global adoption of Edwards’ advanced technologies such as INSPIRIS, MITRIS, and KONECT. The company continues to see an increase in surgical procedures, including complex cases, and is actively expanding the RESILIA product line. Notable milestones include CE Mark approval for KONECT in Europe and the launch of MITRIS in China.

Challenges Facing Edwards Lifesciences

Despite its successes, Edwards faces several headwinds, including rising inflation, supply chain disruptions due to geopolitical tensions, and evolving regulatory requirements. Additionally, staffing shortages in hospital systems are impacting operations.

Financial Outlook

Analysts expect Edwards Lifesciences’ earnings per share to climb by 14.8% in 2026 to $2.94, and by 12.2% in 2027 to $3.30, according to the Zacks Consensus Estimate. Over the past month, the 2026 EPS estimate has increased by 2.1%.

Revenue is projected to rise 9.6% to $6.65 billion in 2026 and grow another 9.8% to $7.30 billion in 2027.

Other Noteworthy Medical Stocks

Other high-performing stocks in the medical sector include Globus Medical, Intuitive Surgical, and Phibro Animal Health.

• Globus Medical boasts an earnings yield of 4.9%, well above the industry average of -0.7%. The company exceeded earnings expectations in three of the last four quarters, with an average surprise of 18.8%. Its shares have climbed 22.3% over the past year, outpacing the sector’s decline. GMED currently holds a Zacks Rank #1 (Strong Buy).
• Intuitive Surgical, also rated Zacks Rank #1, has an earnings yield of 2.1% compared to the industry’s -0.7%. While its shares dipped 0.9% over the past year, this was far less than the industry’s 39% drop. The company beat earnings estimates in each of the last four quarters, with an average surprise of 13.2%.
• Phibro Animal Health currently holds a Zacks Rank #1 and reports an earnings yield of 6.1%, surpassing the industry’s 2.6%. Its shares have soared 130.6% in the past year, while the industry fell by 17.9%. The company exceeded earnings expectations in all four recent quarters, averaging a 20.2% surprise.

Spotlight: Zacks Top 10 Stocks for 2026

There’s still time to get early access to Zacks’ top 10 stock picks for 2026. Curated by Zacks Director of Research Sheraz Mian, this portfolio has delivered remarkable and consistent results.

Since its inception in 2012 through November 2025, the Zacks Top 10 Stocks have achieved a cumulative gain of +2,530.8%, outpacing the S&P 500’s +570.3% return by more than fourfold.

Sheraz has carefully selected the best 10 stocks from over 4,400 companies covered by the Zacks Rank for 2026. You can be among the first to discover these newly released picks with significant growth potential.

Additional Resources

Looking for the latest stock recommendations from Zacks Investment Research? Download the 7 Best Stocks for the Next 30 Days for free.